NASDAQ:IMDX Oncocyte Q4 2025 Earnings Report $3.44 -0.03 (-0.86%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$3.52 +0.08 (+2.18%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncocyte EPS ResultsActual EPS-$0.27Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncocyte Revenue ResultsActual Revenue$1.14 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncocyte Announcement DetailsQuarterQ4 2025Date3/26/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Oncocyte Earnings HeadlinesOncocyte (NASDAQ:IMDX) Stock Rating Cut to Sell at Wall Street ZenOctober 3 at 1:25 AM | americanbankingnews.comContrasting Oncocyte (IMDX) & Its CompetitorsOctober 1 at 6:31 AM | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 3 at 1:00 AM | Banyan Hill Publishing (Ad)Head to Head Analysis: Oncocyte (IMDX) and The CompetitionOctober 1 at 5:44 AM | americanbankingnews.comComparing Precision BioSciences (NASDAQ:DTIL) & Oncocyte (NASDAQ:IMDX)October 1 at 4:58 AM | americanbankingnews.comAnalyzing Oncocyte (IMDX) & Its RivalsSeptember 29, 2026 | americanbankingnews.comSee More Oncocyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email. Email Address About OncocyteOncocyte (NASDAQ:IMDX)oration is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy. The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy. Oncocyte has also pursued tests for evaluating the likelihood that lung nodules are malignant. Oncocyte was founded in 2009 and has focused primarily on oncology applications in the United States, working with physicians, laboratories, and health care providers. The company has undergone strategic and corporate changes over time, including transactions involving its diagnostic assets. Publicly available information about its current leadership and operations under the NASDAQ symbol IMDX is limited.View Oncocyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
